FibroBiologics Files 2024 Second Quarter Report
Rhea-AI Summary
FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission. The company specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. FibroBiologics boasts a portfolio of over 150 issued and pending patents in this field. The quarterly report, which provides detailed financial and operational information for the second quarter of 2024, is now available for public viewing through a link on the company's investor relations website.
Positive
- Portfolio of 150+ issued and pending patents
- Clinical-stage biotechnology company status
- Focus on potential cures for chronic diseases
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, FBLG declined 39.41%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission.
The filing can be viewed through a link on FibroBiologics’ website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is FibroBiologics' stock symbol?
When did FibroBiologics file its 2024 Q2 report?
What is FibroBiologics' main focus in biotechnology?
How many patents does FibroBiologics have?
